Generic Name and Formulations:
Natamycin 5%; oph susp; contains benzalkonium chloride 0.02%.
Alcon Laboratories, Inc.
Indications for NATACYN:
Treatment of fungal blepharitis, conjunctivitis, and keratitis due to susceptible organisms including Fusarium solani keratitis.
Keratitis: initially 1 drop in the conjunctival sac at hourly or two-hourly intervals. May reduce to 1 drop 6–8 times daily after the first 3–4 days. Continue for 14–21 days or until resolution. Reduce dose gradually at 4–7 day intervals to assure replicating organism is eliminated. Blepharitis, conjunctivitis: less frequent initial dosage (4–6 daily applications) may be sufficient.
Reevaluate if no improvement after 7–10 days. Monitor at least twice weekly; discontinue if drug toxicity occurs. Pregnancy (Cat. C). Nursing mothers.
Conjunctival chemosis and hyperemia.
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- HbA1c Levels Predictive of Liraglutide Treatment Response in T2D
- Clinicians May Be Overtreating Older Patients With Diabetes
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Diabetes May Decrease Ability to Feel Acid Regurgitation
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Hormonal Contraceptives May Adversely Affect Psychological Health in Adolescent Girls
- Obesity Can Negatively Effect Liver in Children as Young as 8
- Recommendations Developed on Gender Equity in Medicine